Analytical Data
-
Gene name
Peptide Ready HLA-A*02:01&B2M Monomer
- Application
-
Alternative Names
MHC; HLA-A*02:01; Peptide Ready
-
Species
Human
-
Source
HEK293
-
Tag
C-8*His;C-Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)
-
Molecular Weight
50-60 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the Peptide Ready HLA-A*02:01&B2M monomer recombinant protein is crucial in the fields of immunology and vaccine development. HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) class I molecules, playing a pivotal role in the immune response by presenting peptide antigens to CD8+ T cells. Its relevance is underscored by its association with various diseases, including viral infections and cancers. The B2M (beta-2-microglobulin) component is essential for the stability and surface expression of HLA class I molecules. Researchers have focused on creating a stable, recombinant form of HLA-A*02:01 complexed with B2M to facilitate the study of T cell responses and the development of peptide-based immunotherapies. By utilizing this monomer, scientists aim to enhance the understanding of T cell receptor interactions, evaluate the immunogenicity of specific peptide epitopes, and design novel vaccines that can elicit robust immune responses. Furthermore, the Peptide Ready HLA-A*02:01&B2M monomer serves as a platform for high-throughput screening of peptide libraries, enabling the identification of optimal vaccine candidates and therapeutic targets. The insights gained from this research could lead to innovative approaches for the prevention and treatment of infectious diseases and cancers, showcasing the importance of HLA-A*02:01 in personalized medicine and immunotherapy.
